PF-Atlas › Clinical Trials › NCT00318175

Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis

Bosentan · Phase 2

Registry ID
NCT00318175
Phase
Phase 2
Status
Completed
Drug / intervention
Bosentan (Tracleer)
Sponsor
Heinrich-Heine University, Duesseldorf
Start
2006-06
Enrollment
10
Locations
1

About this trial

Endothelin-1 is a potent vasoconstrictor and binds to two receptors, ET-A and ET-B, which are variable expressed on endothelial cells, smooth muscle cells, and fibroblasts. Furthermore, endothelin-1 has been found to be released in vitro by scleroderma fibroblasts and could contribute to the development of dermal fibrosis in systemic sclerosis. Bosentan is a dual receptor antagonist, that competes with the binding of endothelin-1 to both receptors and has already been approved for the treatment of pulmonary arterial hypertension in Europe, the US, and some other countries. The purpose of this study is to evaluate the effect of bosentan treatment on skin fibrosis and functionality in patients with systemic sclerosis.

View NCT00318175 on ClinicalTrials.gov →

Explore related

All Bosentan trialsAll IPF trials

Related trials

Bosentan — NCT00070590bosentan — NCT00625469bosentan — NCT01518595Bosentan — NCT00631475bosentan — NCT00071461Bosentan — NCT00637065
Medical disclaimer. This page summarizes public trial data for NCT00318175 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.